{"entity":{"id":"acorep-drc","kind":"institution","name":"Autorité Congolaise de Réglementation Pharmaceutique (ACOREP)","aka":["ACOREP","Congolese Pharmaceutical Regulatory Authority","Direction de la Pharmacie et du Médicament","DPM RDC"],"tldr":"The Democratic Republic of the Congo's medicines regulator since March 2020. It grants five-year marketing authorisations, publishes a register of authorised medicines, and authorises clinical trials after ethics approval.","summary":"ACOREP was created by Decree No. 20/002 of 5 March 2020 as a public body under the Ministry of Public Health, taking over the equipment and infrastructure of the Directorate of Pharmacy and Medicine and of the national quality control laboratory, according to NIAID's ClinRegs profile of the country (reviewed 16 December 2025). It regulates medicines, foods, medical devices, herbal products, cosmetics and psychotropic drugs, runs the national pharmacovigilance system, and authorises clinical trials: ClinRegs reports that a trial needs a favourable opinion from an ethics committee such as the National Committee of Health Ethics (CNES), that ACOREP decides on a complete application within 30 days, and that the fee for a phase III trial funded by a non-resident sponsor is 3,000 US dollars. The coordinates are an approximate Kinshasa city point; ClinRegs gives its address as Boulevard du 30 juin.\n\nOn 4 February 2026 ACOREP posted its register of marketing authorisations, a 355-page PDF. Read on 11 November 2026, its entries were registered in 2021, 2022 and 2024 and each is valid for five years. About 40 entries are classed as anticancer or antineoplastic, among them rituximab, bevacizumab, atezolizumab, pertuzumab with trastuzumab, imatinib, dasatinib, docetaxel, paclitaxel, capecitabine, anastrozole, letrozole and abiraterone. Its Director General, Christian Ntumba Ngoy, was appointed by presidential ordinance No. 22/136 of 29 August 2022, according to its site.","asOf":"2026-11-11","links":[{"label":"ACOREP (home page)","url":"https://acorep.gouv.cd/"},{"label":"ACOREP: répertoire des médicaments autorisés (4 February 2026)","url":"https://acorep.gouv.cd/repertoire-des-medicaments-autorises/"},{"label":"NIAID ClinRegs: Democratic Republic of the Congo, regulatory authority and clinical trial requirements","url":"https://clinregs.niaid.nih.gov/country/drc"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["drc-ministry-of-health"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Kinshasa","country":"CD","lat":-4.31,"lng":15.31,"institutionType":"government","website":"https://acorep.gouv.cd/","programs":["Marketing authorisation of medicines (five-year validity)","Register of authorised medicines (posted 4 February 2026)","Clinical trial authorisation","National pharmacovigilance system","Provincial divisions (Kinshasa, Haut-Katanga, Kongo Central)"]},"route":"/institutions/acorep-drc/","neighbours":{"institution":[{"id":"drc-ministry-of-health","kind":"institution","name":"Ministry of Public Health, Hygiene and Social Welfare, Democratic Republic of the Congo","route":"/institutions/drc-ministry-of-health/"}]}}